Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefan Duensing

Showing results (111-120 of 139) with videos related to

Pageof 14
Sort By:
Oncotarget|December 16, 2016
MED15 overexpression in prostate cancer arises during androgen deprivation therapy via PI3K/mTOR signalingAnne Offermann, Ignacija Vlasic, Isabella Syring, et al.
Frontiers in Oncology|January 9, 2019
Expression of Prostate-Specific Membrane Antigen (PSMA) on Biopsies Is an Independent Risk Stratifier of Prostate Cancer Patients at Time of Initial DiagnosisMarie Christine Hupe, Christian Philippi, Doris Roth, et al.
European Urology Focus|November 28, 2018
Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for the Prediction of Extraprostatic Disease-A Risk Model for Patient-tailored Risk Stratification When Planning Radical ProstatectomyJoanne Nyarangi-Dix, Manuel Wiesenfarth, David Bonekamp, et al.
Oncotarget|July 25, 2016
Ago-RIP-Seq identifies Polycomb repressive complex I member CBX7 as a major target of miR-375 in prostate cancer progressionJulia M A Pickl, Diana Tichy, Vladimir Y Kuryshev, et al.
Cancer Immunology, Immunotherapy : CII|December 23, 2022
BAP1 and PTEN mutations shape the immunological landscape of clear cell renal cell carcinoma and reveal the intertumoral heterogeneity of T cell suppression: a proof-of-concept studyJana Friedhoff, Felix Schneider, Christina Jurcic, et al.
Diagnostics (Basel, Switzerland)|April 13, 2024
PD-L1 as a Urine Biomarker in Renal Cell Carcinoma-A Case Series and Proof-of-Concept StudyPhilipp Reimold, Georgi Tosev, Adam Kaczorowski, et al.
The Journal of Clinical Investigation|October 9, 2002
PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesisDipak Panigrahy, Samuel Singer, Lucy Q Shen, et al.
Genes, Chromosomes & Cancer|March 27, 2020
Immuno-oncology gene expression profiling of formalin-fixed and paraffin-embedded clear cell renal cell carcinoma: Performance comparison of the NanoString nCounter technology with targeted RNA sequencingSuranand B Talla, Eugen Rempel, Volker Endris, et al.
Endocrine-Related Cancer|June 19, 2014
MED12 overexpression is a frequent event in castration-resistant prostate cancerDavid Adler, Anne Offermann, Martin Braun, et al.
Translational Oncology|December 23, 2015
Prognostic Significance and Functional Role of CEP57 in Prostate CancerJosef Mang, Nina Korzeniewski, Dimo Dietrich, et al.
Pageof 14

Showing results (111-120 of 139) with videos related to

Sort By:
Pageof 14
Oncotarget|December 16, 2016
MED15 overexpression in prostate cancer arises during androgen deprivation therapy via PI3K/mTOR signalingAnne Offermann, Ignacija Vlasic, Isabella Syring, et al.
Frontiers in Oncology|January 9, 2019
Expression of Prostate-Specific Membrane Antigen (PSMA) on Biopsies Is an Independent Risk Stratifier of Prostate Cancer Patients at Time of Initial DiagnosisMarie Christine Hupe, Christian Philippi, Doris Roth, et al.
European Urology Focus|November 28, 2018
Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for the Prediction of Extraprostatic Disease-A Risk Model for Patient-tailored Risk Stratification When Planning Radical ProstatectomyJoanne Nyarangi-Dix, Manuel Wiesenfarth, David Bonekamp, et al.
Oncotarget|July 25, 2016
Ago-RIP-Seq identifies Polycomb repressive complex I member CBX7 as a major target of miR-375 in prostate cancer progressionJulia M A Pickl, Diana Tichy, Vladimir Y Kuryshev, et al.
Cancer Immunology, Immunotherapy : CII|December 23, 2022
BAP1 and PTEN mutations shape the immunological landscape of clear cell renal cell carcinoma and reveal the intertumoral heterogeneity of T cell suppression: a proof-of-concept studyJana Friedhoff, Felix Schneider, Christina Jurcic, et al.
Diagnostics (Basel, Switzerland)|April 13, 2024
PD-L1 as a Urine Biomarker in Renal Cell Carcinoma-A Case Series and Proof-of-Concept StudyPhilipp Reimold, Georgi Tosev, Adam Kaczorowski, et al.
The Journal of Clinical Investigation|October 9, 2002
PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesisDipak Panigrahy, Samuel Singer, Lucy Q Shen, et al.
Genes, Chromosomes & Cancer|March 27, 2020
Immuno-oncology gene expression profiling of formalin-fixed and paraffin-embedded clear cell renal cell carcinoma: Performance comparison of the NanoString nCounter technology with targeted RNA sequencingSuranand B Talla, Eugen Rempel, Volker Endris, et al.
Endocrine-Related Cancer|June 19, 2014
MED12 overexpression is a frequent event in castration-resistant prostate cancerDavid Adler, Anne Offermann, Martin Braun, et al.
Translational Oncology|December 23, 2015
Prognostic Significance and Functional Role of CEP57 in Prostate CancerJosef Mang, Nina Korzeniewski, Dimo Dietrich, et al.
Pageof 14